Salvador Fudio

8PUBLICATIONS
27CO-AUTHORS
Predictive and prognostic markersCancer geneticsToxicology (incl. clinical toxicology)Liquid biopsiesPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Mar 27, 2025
CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor Lurbinectedin.

Rubin Lubomirov, Laura Pérez-Ramos, Salvador Fudio

|Jan 08, 2025
Description and Modeling of Relevant Demographic and Laboratory Variables in a Large Oncology Cohort to Generate Virtual Populations.

Laura Pérez-Ramos, Laura Ibarra-Gómez, Rubin Lubomirov

|Apr 26, 2024
Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study.

Irene Moreno, Tatiana Hernández, Emiliano Calvo

|Feb 24, 2024
Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction Study.

Irene Moreno, Tatiana Hernández, Emiliano Calvo

|Jan 11, 2022
Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.

Jose F Varona, Pedro Landete, Jose A Lopez-Martin

|Nov 05, 2021
Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer.

Carlos Fernández-Teruel, Salvador Fudio, Rubin Lubomirov

Pageof 2

Frequent Collaborators

6 joint publications

Rubin Lubomirov

3 joint publications

Carlos Fernandez-Teruel

2 joint publications

Eduardo Asín-Prieto

2 joint publications

Tatiana Hernández